What a focal hip cartilage defect actually is

Cartilage inside the hip joint cannot repair itself. Once the hyaline cartilage lining the femoral head or acetabulum is worn through to a significant depth, the body lacks the cell machinery to lay fresh tissue down — which is precisely why the type and extent of the damage matters so much when weighing treatment options.

A focal cartilage defect is a localised, full- or near-full-thickness chondral lesion sitting within an otherwise relatively intact joint surface. Think of a pothole in a road that is otherwise sound: the surrounding tarmac holds up, but the hole itself will not fill unless something is done about it. That is quite different from a road whose surface is crumbling throughout — which more closely describes the diffuse, pan-articular wear seen in advanced hip osteoarthritis affecting the whole joint.

The distinction is clinically important because it drives treatment choice. Patients with a focal Grade III or IV chondral lesion — classified by depth of damage, with Grade IV reaching subchondral bone — and healthy cartilage bordering the defect are the primary candidates for scaffold-based repair approaches such as ChondroFiller™. The intact surrounding tissue provides the biological framework within which a scaffold can be anchored and populated by the body's own cells.

PRP, by contrast, works through biochemical signalling rather than structural scaffolding, and its indication range extends to broader patterns of degeneration, tendinopathy, and diffuse cartilage wear where a localised scaffold would not address the full picture. Understanding which pattern applies to your hip — focal or diffuse — is therefore the starting point for any meaningful comparison of these two treatments.

How ChondroFiller™ works as an injectable hip scaffold

ChondroFiller™ (Meidrix Biomedicals GmbH, Germany) is a CE-marked Class III medical device: an acellular, acid-extracted Type I collagen scaffold delivered as a single ultrasound-guided intra-articular injection into the hip. No incisions, no operating theatre, no general anaesthetic — the procedure takes place in an outpatient clinic under local anaesthesia or mild sedation.

Once injected, the high-viscosity collagen polymerises in situ, forming a biological layer directly over the damaged joint surface. What follows is a process clinicians call acellular matrix-induced chondrogenesis — the scaffold contains no cells of its own but instead creates a three-dimensional protein environment that the body's own progenitor cells, drawn from the synovium and subchondral bone, migrate into and gradually remodel into cartilage-like tissue over subsequent months. The treatment supports the body's own repair processes rather than replacing them synthetically.

This is a top-down, additive approach: existing joint structures are preserved and nothing is surgically removed. The indication is narrow by design. ChondroFiller™ targets isolated focal Grade III/IV chondral defects with healthy cartilage at the borders — the profile already described — rather than the diffuse, pan-articular wear of advanced hip osteoarthritis.

Published hip-specific data provide the clearest outcome anchors. In studied patients, ChondroFiller™ produced a mean Harris Hip Score improvement of approximately +33 points, with MOCART MRI cartilage regeneration scores in the range of 70–87 across joint applications. More than 19,000 cases have been performed globally, including published evidence in focal hip cartilage damage associated with femoroacetabular impingement (FAI). These figures are cited anchors, not guarantees — outcomes vary by defect size, the quality of surrounding cartilage, and individual biology.

What PRP does and where it fits in hip cartilage care

Produced from the patient's own blood, PRP (platelet-rich plasma) needs no donor tissue and no imported material. A small blood draw is centrifuged to remove red blood cells and concentrate the platelet fraction to at least twice its baseline level; the resulting plasma is then placed into the hip joint under ultrasound guidance as an outpatient intra-articular injection. The whole process takes place in a clinic setting without general anaesthetic.

The mechanism is biochemical, not structural. Platelets are rich in signalling proteins — among them fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) — that, once released into the joint environment, may stimulate resident cells, modulate inflammation, and support the biological conditions for tissue maintenance. PRP does not provide a physical repair layer; it influences the environment in which the body's own cells operate.

That distinction shapes where PRP sits in the hip care pathway. Its indication range is broader than ChondroFiller™'s: published data support its use in mild-to-moderate hip osteoarthritis, diffuse cartilage wear, tendinopathy, and ligament pathology around the hip joint — conditions where the problem is not a discrete structural defect requiring a scaffold. Comparative data show PRP outperforming hyaluronic acid for functional outcomes at 28 weeks and suggest it may postpone the need for surgical referral. Used alongside microfracture, PRP has also produced better pain and functional results than microfracture alone, pointing to its value as a biological augmentation strategy rather than a standalone structural fix.

A known limitation is preparation variability. Leukocyte-rich (LR-PRP) and leukocyte-poor (LP-PRP) formulations appear to have different biological effects, and platelet concentration, injection frequency, and processing protocol all differ between providers. Evidence from one PRP study cannot be straightforwardly applied to another without knowing the preparation details — a point worth raising during any consultation.

ChondroFiller™ vs PRP: which suits which hip patient

The clinical logic of each treatment points in different directions, which is why the question is rarely 'which is better?' but 'better for what?'

ChondroFiller™ — the focal-defect profile

ChondroFiller™ is built around a single structural task: placing a biological scaffold over an isolated, well-defined lesion. The ideal candidate has a focal Grade III/IV chondral defect with healthy cartilage at the surrounding borders and an otherwise preserved hip joint — not diffuse pan-articular wear. Assessing suitability typically involves four dimensions: the mechanical load environment the defect sits in (physics), the biological quality of the surrounding tissue (chemistry), the patient's own repair capacity (biology), and how long the defect has been present and progressing (timing). Together these lenses help determine whether conditions exist for the scaffold to recruit and retain the patient's progenitor cells effectively.

PRP — the broader degeneration profile

PRP suits a different clinical picture. Patients with mild-to-moderate hip osteoarthritis, diffuse cartilage wear, or soft-tissue involvement — tendinopathy, ligament pathology — around the hip are more likely to benefit from PRP's biochemical environment support than from a scaffold aimed at a focal lesion. PRP is also used as a biological augmentation alongside other procedures rather than as a standalone structural repair.

Combination use

The two treatments are not mutually exclusive. Some patients with a focal lesion may benefit from ChondroFiller™ as the scaffold component and PRP to enrich the biological environment that surrounds it. When this combination is considered, the mechanisms remain distinct: ChondroFiller™ provides the physical layer; PRP provides the growth-factor signalling. They should not be described as duplicating each other or collapsed into a generic 'filler' category.

The evidence gap — stated plainly

No randomised controlled trial has yet compared ChondroFiller™ directly against PRP specifically in the hip. The clinical rationale for each is supported individually — what differs is the indication, not the evidence standard — but direct comparative data in this joint are not yet published. That gap does not dissolve the distinction between a scaffold treatment for a focal lesion and a biochemical support treatment for broader degeneration; it simply means the comparison rests on mechanism and indication logic rather than a single head-to-head trial.

The injection pathway and access in Lincolnshire

For Lincolnshire patients, the practical question once a treatment direction is being considered tends to be about access rather than mechanism.

The hip's anatomy makes image guidance essential for any intra-articular injection: the femoral head sits deep within a thick envelope of muscle and soft tissue, so blind placement is unreliable. Both ChondroFiller™ and PRP are placed under ultrasound or fluoroscopic guidance to confirm needle position before the product is delivered — a standard that applies regardless of which injectable is chosen.

ChondroFiller™ is available locally through Lincolnshire Hip, with appointments in Grantham or Sleaford under Professor Paul Lee. Patients do not need to travel to London. The treatment is self-funded private care — not currently available through the NHS or standard private medical insurance — and UK pricing is structured as guide costs covering one, two, or three boxes depending on the size and number of defects being treated. Each tier is all-inclusive: consultation, ultrasound guidance, the product, and a six-week follow-up appointment are all within the single fee. Exact guide costs should be confirmed directly with the clinic.

PRP is similarly delivered as an outpatient injection. Because PRP is produced from the patient's own blood, centrifugation and processing take place on the day of the appointment before the injection itself — an additional step that is straightforward but worth factoring into scheduling.

Neither pathway requires a GP referral to begin assessment. Lincolnshire Hip is part of the MSK Doctors group and accepts patients directly for hip evaluation.

Questions worth asking before you decide

Arriving at an assessment appointment with the right questions shortens the diagnostic process. Three are worth preparing:

• Does my MRI suggest a focal lesion or more diffuse degeneration? The answer shapes the treatment direction — a scaffold is designed for a well-defined lesion, not generalised wear across the joint.
• What is the quality of the cartilage bordering the affected area? ChondroFiller™ relies on healthy surrounding tissue to contain and retain the scaffold; PRP's growth-factor support is less dependent on lesion geography.
• Have I had previous injections, and what changed? Prior responses to hyaluronic acid, corticosteroid, or PRP provide useful biological signal before any regenerative option is considered.

The self-assessment tool at lincolnshirehip.com applies the four-lens suitability framework described in the previous section — a practical starting point, though not a substitute for clinical review with imaging.

Outcomes for both treatments vary by defect size, surrounding cartilage quality, and individual biology; what realistic improvement looks like should be agreed with a clinician who has seen the relevant scans.

The distinction that runs through this comparison — focal structural lesion versus broader degenerative pattern — ultimately determines which approach, or combination, is most likely to be appropriate. Published outcomes for ChondroFiller™ in focal hip defects include a Harris Hip Score gain of +33 points and MOCART regeneration scores of 70–87; PRP's role is primarily biochemical support across a wider indication range. Matching treatment to that distinction, rather than defaulting to the more complex option, is the clinical starting point.

Appointments at Lincolnshire Hip — part of the MSK Doctors group, with clinics in Grantham and Sleaford — are available for hip assessment without a GP referral.